|
|
|
front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |review |
 |
Key Point:
Depression is a commonly occurring adverse effect of IFN therapy. Screening
for depression starts at the point of contact with subjects considering HCV-therapy,
and remains a routine assessment throughout the treatment period.
Subjects with preexisting neuropsychiatric disorders are frequently managed by a psychiatrist. References PEGASYS® Complete Product Information. Nutley, NJ: Hoffman-La Roche Inc; 2002. PegIntron [package insert]. Kenilworth, NJ: Schering Corporation; 2001. |